RxDoctor Payments DataLook up a doctor →

Kumar Ramdas, MD

Internal Medicine · Maplewood, NJNPI 1780663898

Payments from drug & device makers

$86,582in general payments, 2019–2025

Across 1,131 payments — averaging $76.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$42K
  • GSK$20K
  • Johnson & Johnson$10K
  • AstraZeneca$3K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)193$42,213
GSK39$20,178
Johnson & Johnson40$9,912
AstraZeneca163$2,619
Boehringer Ingelheim72$1,465
Lilly USA, LLC100$1,428
Merck66$965
Madrigal Pharmaceuticals8$679
Amgen(2 entities)55$678
Novartis43$575
Sanofi-aventis U.S. LLC29$538
Sumitomo Pharma America, Inc.34$400
Sunovion Pharmaceuticals Inc.30$351
Travere Therapeutics, Inc.21$347
Pfizer18$272
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$252
Intra-sana Laboratories6$247
Dexcom, Inc.12$222
Otsuka America Pharmaceutical, Inc.13$205
Vifor Pharma, Inc.17$204
E.r. Squibb & Sons, L.L.C.11$198
Kowa Pharmaceuticals America, Inc.13$187
Scilex Pharmaceuticals Inc.13$186
Astellas Pharma US Inc8$178
Medtronic1$165
ANI Pharmaceuticals, Inc.9$159
Abbott8$155
Takeda Pharmaceuticals U.S.A., Inc.13$151
Amarin Pharma, Inc.9$130
Xeris Pharmaceuticals, Inc.8$126
Phathom Pharmaceuticals, Inc.1$125
Abiomed1$123
Mannkind Corporation7$101
Arbor Pharmaceuticals, Inc.6$84
Ironwood Pharmaceuticals, Inc4$60
Nabriva Therapeutics, PLC4$55
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$54
Biohaven Pharmaceutical Holding Company Ltd.3$46
Teva Pharmaceuticals USA, Inc.3$42
Bayer2$38
Valeritas, Inc.2$37
Lundbeck LLC2$33
Embecta Corp.2$32
Vanda Pharmaceuticals Inc.2$32
Azurity Pharmaceuticals, Inc.2$31
Exact Sciences1$30
Paratek Pharmaceuticals, Inc.2$30
Avanir Pharmaceuticals, Inc.2$29
Endo Pharmaceuticals Inc.2$28
Gilead2$27
Grifols USA, LLC1$24
Amphastar Pharmaceuticals, Inc.1$19
Neurelis, Inc.1$17
Neurocrine Biosciences, Inc.1$16
Acadia Pharmaceuticals Inc1$16
Esperion Therapeutics, Inc.1$16
Mayne Pharma Commercial LLC1$15
Aytu Biopharma, Inc.1$14
Radius Health, Inc.1$13
Mylan Specialty L.p.1$13

How this compares

$86,582 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024
$334,601
Medicare patients
548
Services billed
4,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Maplewood

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →